• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Allergan Stock Slips Despite Beat and Raised Guidance

Shares of the maker of Botox are struggling despite its latest results exceeding expectations.
By KEVIN CURRAN May 07, 2019 | 08:59 AM EDT
Stocks quotes in this article: AGN

Allergan (AGN) isn't standing firm on Tuesday morning despite strong results from Botox and other products.

Shares of the Dublin-based pharmaceutical company were down nearly 2% before Tuesday's opening bell even though Allergan reported first-quarter beats on its top and bottom lines and raised its 2019 forecast above prior estimates.

"Our first-quarter results reflected continued growth of our Core Business, which increased 4.4% year-over-year across our four key therapeutic areas. Growth of key products such as BOTOX Cosmetic, BOTOX Therapeutic, VRAYLAR, JUVÉDERM and Lo LOESTRIN offset declines in products that lost exclusivity and products which were divested in 2018," Allergan CEO Brent Saunders said. "Many key R&D programs have made steady progress and we now anticipate five regulatory approvals over the next 18 months."

The regulatory approvals and research-and-development efforts will be keys for Allergan to restore shareholder value after a series of setbacks that recently included the failure of its depression drug rapastinel. Many observers hope it decreases the company's reliance on sales of Botox products, which are still far and away the company's most profitable offerings.

One red flag possibly causing the stock to slip are impairment charges that totaled more than $2 billion.

"GAAP operating loss in the first quarter of 2019 was $2.31 billion, including the impact of impairments," the company's SEC filings released alongside the earnings report reveal. "Non-GAAP operating income in the first quarter of 2019 was $1.63 billion, a decrease of 7.6% versus the prior year quarter, impacted by lower operating margin and revenues due to the impact of divestitures, products that lost exclusivity and declines in textured breast implants and RESTASIS."

The issue is reminiscent of the fourth quarter of 32018, when the company reported pretax impairment charges of $5.4 billion as a result of a write-off related to the planned sale of its anti-infectives unit and a charge from lower-than-expected sales of its double chin treatment Kybella.

"The Company's intended sale of Anti-Infectives and its increased cost of capital based on market dynamics as well as other commercial factors prompted a review of its General Medicine Reporting Unit goodwill," the company explained earlier this year.

The impairments appear to be a persistent issue.

Allergan's management has invoked the ire of activist investors such as David Tepper's Appaloosa LP in the past, with calls for a separation of the chairman and CEO roles currently held by Saunders.

"We again call on the Company to install an independent chairman with suitable experience to bring new leadership to the Board and rein in management's predilection for value-destruction," Tepper's firm said in March. "We view this action as only one in a long list of difficult decisions the Board will need to confront, which may include a change in senior management, separation of business units, merger or sale of the entire Company."

For now, Saunders has dodged the bullet, as shareholders voted to reject the Appaloosa proposal by a majority of 61.3%.

"The Allergan Board appreciates the support of our shareholders reflected in the voting results. We take seriously the feedback we received during our shareholder engagements leading up to the Annual Meeting and look forward to a continued dialogue moving forward," a statement following the annual shareholders meeting last week reads. "Allergan's Board of Directors is dedicated to best-in-class governance, strong independent oversight, accountability for performance and delivering on our strategic priorities to create value for our shareholders."

The vote alleviates at least one management issue while the company contends with a somewhat adversarial political environment and litigation risks surrounding the company's ties to the opioid epidemic.

It will be Saunders who will kick off an earnings call at 8:30 a.m. ET Tuesday in order to encourage the market to trust his management and the company's more bullish goals for 2019.

Click here to tune in.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Activist investing | Regulation | Litigation | Earnings | Investing | Politics | Stocks | Healthcare | Life Sciences | Pharmaceuticals | Real Money

More from Stocks

How to Trade MongoDB After Its Huge Upside Move

Bruce Kamich
Jun 5, 2023 1:45 PM EDT

Let's check out the charts and indicators for clues.

This Value Portfolio of Lovable Losers Is Down But Not Out

Jonathan Heller
Jun 5, 2023 1:10 PM EDT

With about six months to go, anything can happen for the 2023 Tax Loss Selling Recovery Portfolio.

Friday's Cheer Turns to Monday Drear

James "Rev Shark" DePorre
Jun 5, 2023 11:35 AM EDT

Even the bulls will likely agree that this market needs better participation and breadth.

As Palo Alto Networks Joins the S&P 500, Here's How to Play the Stock

Stephen Guilfoyle
Jun 5, 2023 11:24 AM EDT

This 'best-in-class' cybersecurity name was already hot, before the news.

I'm Placing Bets on a Couple of Giants to Lose Ground in the Coming Months

Bret Jensen
Jun 5, 2023 10:10 AM EDT

This pair of household names easily could pull back based on the economic challenges ahead.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login